Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment

Imugene

27/11/2025 01:04

** Shares of Imugene IMU.AX rise as much as 6.2% to A$0.345, the highest since November 6

** The biotechnology company entered a strategic collaboration with JW Therapeutics 2126.HK to evaluate a novel combination therapy to treat refractory solid tumours

** Stock up for the third straight session

** Stock currently up 3.1%, bringing YTD losses to 71.2%

(Reporting by Adwitiya Srivastava in Bengaluru)

((Adwitiya.Srivastava@thomsonreuters.com))